Cannabis Report
Lithium
Home > Boards > Canadian > Biotechs >

Breathtec Biomedical Inc. (BTHCF)

BTHCF RSS Feed
Add BTHCF Price Alert      Hide Sticky   Hide Intro
Moderator: shell3, smoki, hoyowasobo
Search This Board: 
Last Post: 8/14/2018 10:36:58 PM - Followers: 95 - Board type: Free - Posts Today: 0


 
The Future of Disease Detection 

TOTAL AUTHORIZED SHARES: 100,000,000

NUMBER OF OUTSTANDING LISTED SHARES: 57,364,023

WARRANTS ISSUED BUT NOT EXERCISED: 12,011,665

OPTIONS ISSUED BUT NOT EXERCISED: 2,970,000 

FULLY DILUTED SHARES IF ALL WARRANTS & OPTIONS EXERCISED: 72,345,688 


CSE: BTH  XFRA: BTI  OTC: BTHCF    

 
Company Overview
 

Breathtec’s mission is to develop technologies that use biomarkers in the breath to screen for early signs of diseases such as lung & breast cancers, infectious diseases, diabetes, liver disease, and more. We are focused on developing a low-cost, non-invasive, portable hand-held device to be used by clinician’s in the office, clinic or hospital setting, or by agents screening for infectious diseases at national border entry points (ie: airports).

Field Asymmetric Ion-Mobility Spectrometry (FAIMS) is a highly sensitive chemical analysis method previously used for explosives detection that we have readapted for breath analysis for early disease detection.  FAIMS analysis has been successfully used to identify numerous biomarkers associated with disease but previous approaches have had limited clinical use due to a lack of the reproducibility and sensitivity required, as well as the size and expense of the final device. Breathtec’s goal is to leverage our deep understanding of the FAIMS technology in order to develop an effective and affordable medical screening device.

Regular screening using a simple breath test, could lead to significant advancements in remedial treatment protocols targeting major improvements in survivability and life quality.

 

 
Learn More ›


 
Technology Overview


Breathtec Biomedical Inc. (“Breathtec”) aims to propel development and commercialization of breath analysis screening technologies.

Breathtec holds a license to key University of Florida patent U.S. 8,237,118 entitled “Partial Ovoidal FAIMS Electrode.”

FAIMS is a mass spectrometry technique that exploits differences in ion mobility at very high electric fields, to separate ions in the millisecond timescale after liquid chromatography separation and prior to introduction to a mass spectrometer.

FAIMS technology allows for miniaturization of breath testing devices and will enable development of non-invasive clinical screening.

Eventual commercialization of FAIMS could revolutionize early detection of many deadly diseases.

The Company is actively pursuing multiple, alternative research efforts into FAIMS technology.

“Every individual has a breath print that differentiates them from other people, depending on what’s going on in their body, and that print can tell us a lot about a person, what they’ve been exposed to and what disease they have. That’s what makes the new field of breath testing so promising, because it is non-intrusive, so there is no risk involved, and you can do it anywhere, in a clinic, in a hospital, anywhere.”

Dr. Raed Dweik, Respiratory Institute at Cleveland Clinic 


Learn More >


 
In The Media 

 
Breathtec Biomedical Set to Blaze Trails in MedTech with Breath Analysis

Bill Gates made the news this week with comments that warned of a rapid epidemic. At the Munich Security Conference in Germany, Gates said, “Whether it occurs by a quirk of nature or at the hand of a terrorist, epidemiologists say a fast-moving airborne pathogen could kill more than 30 million people in less than a year. And they say there is a reasonable probability the world will experience such an outbreak in the next 10 to 15 years.”

While Gates comments focused on the progress in vaccine supply chains, the underlying idea of his words are that the world needs a wake-up call about disease prevention. However, there have been important discoveries in modern science and medical equipment that are transforming the space.

It is actually the rise of early-detection diagnostic devices that might have the biggest impact on saving lives in the future. Advancements that allow physicians to efficiently assess a patient’s medical condition are invaluable not only in the time of a crisis but in the day-to-day healthcare market. Breathtec Biomedical Inc. (BTH:CSE) (BTHCF) is a leading innovator in this space.

Breathtec today provided a corporate update of significant developments and the outlook for near-term opportunity. The company’s diagnostic portfolio includes its proprietary FAIMs technology and the NaNose technology.


Breathtec is Improving Upon Its Innovative Design

Breathtec has completed testing on the V2 prototype for its flagship FAIMS technology. The new design is sleeker and its non-radioactive ionization source and a new square wave generation system remain efficient and agile. The company will patent the new design features specifically the improvement to miniaturized FAIMS cells and the miniaturization of all high-voltage and low-voltage electronic components. The Company will now begin the performance testing phase of this new V2 prototype to continue to characterize the analytical performance of the system in preparation for a pilot clinical study in the fall of 2017. The company has established a clear path to market and will be scheduling a pre-submission meeting with the FDA in the coming months to receive a complete understanding of the regulatory and clinical testing requirements to commercialize the technology.

In addition, Breathtec has expanded its team and brought on experienced consultants to develop a Quality System and Design Control process and finish the creation of these tech platforms.

“We have the right technology and the right team to get to market and will be working diligently to accomplish this in an efficient and time sensitive manner,” Breathtec CEO Guy LaTorre stated. “Our goals are ambitious and challenging but we feel confident that, with your support, we will be able to make significant contributions to the field of breath analysis, which will be worthwhile for the patient, medical community and for our investors.” 


Paradigm Shift: Breathtec’s Early Screening Technology

Based in Florida, Breathtec’s aim is to battle disease through prevention and one’s own breath. Na-Nose, an advanced stage breath analysis, can detect a variety of diseases, including, among others, streptococcus; hemophilus influenza, chickenpox; and the common cold. “Na-Nose was developed using space-age nanotechnology to be extremely sensitive for the detection of multiple trace chemicals or volatile organic compounds in the breath,” stated Dr. Raj Attariwala, lead engineer of Breathtec. “It uses machine learning to effectively sniff our unique patterns of disease processes in the body.”

Technology with the power to recognize diseases that are not even yet showing physical symptoms would be the answered prayer of patients and physicians everywhere. NaNose represents the possibility of a paradigm shift in point-of-care technology and overall quality of life.

The Point-of-Care Diagnosis market is rising and, according to MarketandMarkets.com, is expected to reach $36.96 billion by 2021. Breathtec stands on the precipice of a market that is rising with transformative technology in hand. Investors should continue to watch this company that has serious potential to benefit patient and healthcare providers.

Learn More>


Leadership @ Breathtec Biomedical Inc

headshot_chrisMoreau
Christopher J. Moreau, Chief Executive Officer

Mr. Moreau is a seasoned business professional in the life sciences sector with a strong background in medical devices and biomarker research. Mr. Moreau is currently the CEO of Nash Pharmaceuticals Inc., a privately-held drug development company and was previously President & CEO of Miraculins Inc, a public company where he raised in excess of C$13 million to fund research & development for screening tests for prostate cancer, skin cholesterol and type 2 diabetes.



Michael T. Costanzo, Ph.D., Chief Technical Officer

Dr. Costanzo enjoys a passion for science that has directed his career path firmly into the field of analytical chemistry. Over the past five years he has investigated a variety of advanced experimental methodologies and instrumentation with the Yost Research Group at the University of Florida. During this period he utilized UV spectroscopy to help in standardizing procedures for manufacturing respiratory medications, employed novel ion mobility spectrometric techniques and devices to analyze exhaled breath, and performed multiple metabolomics studies of melanoma. Through his efforts, he acquired a vast knowledge of analytical techniques and methodologies and an immense desire for scientific progress.

Previously, Costanzo obtained his Bachelor of Science in chemistry at the State University of New York (Buffalo). During this period he conducted research under Dr. Troy Wood utilizing mass spectrometry to examine products of enzymatic protein digestion in the interest of studying metabolic markers of autism in children. Upon graduation in 2010 he moved to the University of Florida for Ph.D. studies and as a result of his efforts has recently joined with Breathtec Biomedical to propel his own bioanalytical research through the development of revolutionary clinical devices utilizing his background in ion mobility, mass spectrometry, and exhaled breath analysis.
 


Raj Attariwala, MD, PhD., Lead Engineer

Dr. Attariwala is a dual board certified Radiologist and Nuclear Medicine physician certified in both Canada and the United States. He received his formal medical training at University of British Columbia with periods of specialized medical training at Memorial Sloan Kettering Cancer Centre (New York), UCLA and USC. He holds a doctorate in Biomedical Engineering from Northwestern University (Evanston, IL).

Dr. Attariwala is a practicing physician in British Columbia and owner of AIM medical imaging. He has pioneered advances in the field of whole body medical imaging and authored numerous publications and presented at international medical conferences on whole body imaging and cancer detection.

Dr. Attariwala has extensively investigated breath testing applications and efficacy in a related role at Cannabix Technologies Inc. where he developed a breath testing system for drug impairment.


Image result for richard yost
Richard A. Yost Ph.D., Scientific Advisor

Dr. Yost, Col. Allen R. & Margaret G. Crow Professor and Head of Analytical Chemistry at the University of Florida received his B.S. degree in Chemistry from the University of Arizona in 1974. In 1975 he pursued an NSF graduate fellowship at Michigan State University focusing on electronics and computerized instrumentation. He received his Ph.D. in 1979 and assumed the position of Assistant Professor at the University of Florida and went on to become head of the Analytical Chemistry Division.

Dr. Yost’s research has involved over 100 graduate students funded by over $40 million in research grants, and has published over 160 papers and 16 patents. Over $30 billion worth of instruments have been sold based on these patents.

He serves as a member of the Florida Board of Governors (Regents) and as the Chair of the Advisory Council of Faculty Senates of Florida. He is past Chair of the UF Faculty Senate and served on the UF Board of Trustees. He served as Treasurer and Secretary of the American Society for Mass Spectrometry, and on the editorial boards of The Journal of the American Society for Mass Spectrometry and The International Journal of Mass Spectrometry.

Yost Research Group


- Corporate Links -

Cannabis Report
Lithium
BTHCF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#2063  Sticky Note Commercial Adoption of Ion Mobility Technology Drives Multi-Omics Application shell3 07/23/17 11:38:00 AM
#3944   Law suit or not I am parked here iluv blozf 08/14/18 10:36:58 PM
#3943   Yo iluv blozf: AMG 08/14/18 10:34:23 PM
#3942   A Link To Church! AMG 08/12/18 10:43:16 PM
#3941   I'll try to decode the portion(s) I might AMG 08/11/18 02:30:17 PM
#3940   You said all that without naming what company AMG 08/11/18 01:38:19 PM
#3939   Their going to 'pop' another grant from NIH x1power 08/11/18 01:33:11 PM
#3938   Thanks for the heads up Shell. I'm having AMG 08/10/18 04:16:30 PM
#3937   Kal was shot down on his grab of shell3 08/10/18 03:32:27 PM
#3936   Follow up: The timing of Nash Pharmacueticals Private AMG 08/10/18 11:53:31 AM
#3935   PRIVATE PLACEMENT FOR ACCREDITED INVESTORS--CBD BASED LIVER DISEASE AMG 08/10/18 11:07:37 AM
#3934   A small but significant correction. In my previous AMG 08/09/18 05:22:26 PM
#3933   ...like maybe a 5/4 (20%) R/S and that's AMG 08/09/18 08:27:50 AM
#3932   Good points amg. I have no ILuvblo2 08/09/18 07:53:57 AM
#3931   The timeline for Breathtec's Boneheaded Letter of Intent AMG 08/09/18 03:42:39 AM
#3930   Keeping in mind, Zeptometrix (a Private Company) has AMG 08/08/18 12:51:55 PM
#3929   BreathTec last MD&A shell3 08/08/18 12:09:54 PM
#3928   Correction: Breathtec's Letter Of Intent is to AMG 08/08/18 11:41:47 AM
#3927   Innate becomes the latest loser in MS AMG 08/08/18 11:17:15 AM
#3926   P.S.S. New York Rep. Chris Collins indicted on AMG 08/08/18 10:45:53 AM
#3925   Birds of a feather FreezeThese 08/08/18 10:40:46 AM
#3924   P S. Chris Collins allegedly tipped off Family AMG 08/08/18 10:16:38 AM
#3923   Zeptometrix, Board of Directors, Chris Collins, US Congressman, AMG 08/08/18 09:33:26 AM
#3922   Never underestimate the power of Ants AMG 08/07/18 11:35:19 PM
#3921   Green Day On A Red Day AMG 08/07/18 06:52:10 PM
#3920   Here is the study publication carramrod 08/07/18 06:27:15 PM
#3919   https://www.express.co.uk/life-style/health/998534/Parkinson-disease-Breath-test carramrod 08/07/18 06:00:05 PM
#3918   Breathtec, Nash Pharma, Bullrun AMG 08/07/18 04:43:44 PM
#3917   will not AMG 08/07/18 12:54:44 PM
#3916   These a holes will dilute us to the ILuvblo2 08/07/18 11:16:39 AM
#3915   Self Dealing: AMG 08/07/18 07:10:29 AM
#3914   ...and the thought of folks all converging to AMG 08/07/18 06:36:49 AM
#3913   OK I'm a little disappointed and a little dilligence 08/07/18 04:38:08 AM
#3912   When it all unfolds, I will leave it AMG 08/06/18 11:09:35 PM
#3911   700 W Pender Street - Shareholders Meeting Place shell3 08/06/18 11:02:55 PM
#3910   I stand by my last post. They can't AMG 08/06/18 10:31:05 PM
#3909   And here’s (1) Last thought of NASH Deal shell3 08/06/18 10:21:59 PM
#3908   Meeting was held after BTH New CEO was hired shell3 08/06/18 10:17:20 PM
#3907   That would be a retroactive vote to approve AMG 08/06/18 10:08:23 PM
#3906   d. Please provide the following information as of shell3 08/06/18 09:36:14 PM
#3905   Final thought on a Monday: AMG 08/06/18 08:22:53 PM
#3904   Agreed! smoki 08/06/18 07:19:44 PM
#3903   Funny how your analogy has yet to fit AMG 08/06/18 07:16:58 PM
#3902   Business is Business and it's unfinished my friends. AMG 08/06/18 07:03:55 PM
#3898   groudfloor shareholders always get screwed down here......management sells jaggerxj6 08/06/18 05:54:37 PM
#3897   Letter of Intent : is a document outlining smoki 08/06/18 05:19:10 PM
#3896   Other than havng filed on time, the monthly AMG 08/06/18 04:39:36 PM
#3895   Looks like they may start to give us ILuvblo2 08/06/18 03:52:33 PM
#3894   This is a public company. Give aways, options/warrents, tcm7 08/06/18 02:35:33 PM
#3893   The Wingman posed the same question yesterday. I'm AMG 08/06/18 12:43:22 PM
#3892   Isnt there going to be an official proposal tcm7 08/06/18 11:57:14 AM
PostSubject